TriangleNCT01962792 · OUTCOME
Duration of Response (DOR)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 4 years
What was measured
The time interval between the date of initial documentation of a response (PR or better) and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects who had not progressed/died. The censoring date was the last adequate tumor assessment date.
Analysis population: Please note that the analysis only includes participants who achieved the best response of complete response or partial response from the All-treated population (per protocol).
Groups in this outcome
Cohort 1 (560 mg)
Ibrutinib PO 560 mg + Carfilzomib IV 20/27 mg/m2 Ibrutinib Carfilzomib
Cohort 2a (560 mg)
Ibrutinib PO 560 mg + Carfilzomib IV 20/36 mg/m2 Ibrutinib Carfilzomib
Cohort 2b (560 mg)
Ibrutinib PO 560 mg+ Carfilzomib IV 20/36 mg/m2 Dexamethasone PO 20 mg Ibrutinib Carfilzomib Dexamethasone
All RP2D (840 mg)
Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg Ibrutinib Carfilzomib Dexamethasone
| Group | Source count |
|---|---|
| Cohort 1 (560 mg) | 3 |
| Cohort 2a (560 mg) | 5 |
| Cohort 2b (560 mg) | 17 |
| All RP2D (840 mg) | 59 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort 1 (560 mg) | 7.1 | Not reported | 1.2 | 13.0 | Not reported |
| Cohort 2a (560 mg) | 15.3 | Not reported | 5.4 | 15.3 | Not reported |
| Cohort 2b (560 mg) | 9.2 | Not reported | 3.0 | 14.5 | Not reported |
| All RP2D (840 mg) | 7.2 | Not reported | 2.7 | 16.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.2
- upper Limit
- 13.0
- value
- 7.1
- group Id
- OG001
- lower Limit
- 5.4
- upper Limit
- 15.3
- value
- 15.3
- group Id
- OG002
- lower Limit
- 3.0
- upper Limit
- 14.5
- value
- 9.2
- group Id
- OG003
- lower Limit
- 2.7
- upper Limit
- 16.6
- value
- 7.2
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 5
- group Id
- OG002
- value
- 17
- group Id
- OG003
- value
- 59
- units
- Participants
- description
- The time interval between the date of initial documentation of a response (PR or better) and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects who had not progressed/died. The censoring date was the last adequate tumor assessment date.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Ibrutinib PO 560 mg + Carfilzomib IV 20/27 mg/m2 Ibrutinib Carfilzomib
- id
- OG000
- title
- Cohort 1 (560 mg)
- description
- Ibrutinib PO 560 mg + Carfilzomib IV 20/36 mg/m2 Ibrutinib Carfilzomib
- id
- OG001
- title
- Cohort 2a (560 mg)
- description
- Ibrutinib PO 560 mg+ Carfilzomib IV 20/36 mg/m2 Dexamethasone PO 20 mg Ibrutinib Carfilzomib Dexamethasone
- id
- OG002
- title
- Cohort 2b (560 mg)
- description
- Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg Ibrutinib Carfilzomib Dexamethasone
- id
- OG003
- title
- All RP2D (840 mg)
- param Type
- MEDIAN
- population Description
- Please note that the analysis only includes participants who achieved the best response of complete response or partial response from the All-treated population (per protocol).
- reporting Status
- POSTED
- time Frame
- Up to 4 years
- title
- Duration of Response (DOR)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice